Clinical Research Details
Title:
An Intensive QT/QTc Companion Study to Investigate the Effects of SGN-35 on Cardiac Ventricular Repolarization in Patients With Cancer
Purpose:
The purpose of this study is to evaluate the effect of treatment with SGN-35 on cardiac ventricular repolarization in cancer patients.
Study Number:
202109082609
Number of Patients:
50
Elgibility:
To be eligible, the patient:
Must be enrolled in a clinical trial using SGN-35.
Must be greater than 18 years of age.
Cannot have a clinically significant cardiac history.
Treatment:
You will have a heart monitor placed on you before the infusion of the treatment drug, SGN-35. Readings will be taken at different points in time on day one and day three of cycle one and day one of cycle two. The heart monitor will be attached to you for about 5.5 hours on day one and 2.5 hours on day two.
Principal Investigator:
Enrollment Phone:
(708) 327-3223